Persistent Inflammatory Cells in Blood After Severe Asthma Treatment, New Study Finds
A groundbreaking study reveals that inflammatory immune cells remain in the blood of severe asthma patients even after biologic treatment, highlighting the need for further research into long-term effects and treatment strategies.
A recent study conducted by researchers at Karolinska Institutet in Sweden reveals that biologic therapies used for treating severe asthma may not completely eliminate inflammatory immune cells from the bloodstream. Despite significant improvements in patient symptoms, certain immune cells with high inflammatory potential persist or even increase during treatment with biologics like mepolizumab and dupilumab. These drugs, which target specific pathways involved in asthma inflammation, have transformed severe asthma management, but their long-term impacts on immune cell behavior are not fully understood.
The study analyzed blood samples from 40 patients before and during biologic therapy. Surprisingly, instead of diminishing, some key inflammatory immune cells actually showed elevated levels during treatment. This finding suggests that biologics might not address the root causes of airway inflammation entirely, raising questions about the potential for inflammation to recur once treatment is tapered or discontinued.
Utilizing advanced techniques like flow cytometry and single-cell sequencing, the research team identified these changes in immune cell profiles. The results could explain why airway inflammation often returns after stopping or reducing biologic therapy. Since biologics have been in use for less than a decade, the long-term effects on immune function remain largely unknown.
Further research aims to investigate long-term immune cell behavior and the effects on lung tissue, with ongoing studies focusing on patients with extended treatment histories. Understanding whether these immune cells contribute to persistent inflammation could be vital for developing more effective, lasting treatments for severe asthma.
This study emphasizes the importance of continued monitoring and research into the immunological impacts of biologic therapies, ensuring that treatment strategies evolve to achieve sustained remission in severe asthma patients.
Source: https://medicalxpress.com/news/2025-06-inflammatory-cells-blood-treatment-severe.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Impact of Spinal Cord Injuries on Bladder Control and Emerging Treatment Insights
Recent studies reveal molecular pathways involved in neurogenic bladder caused by spinal cord injuries and explore potential treatments using inosine to protect bladder tissue and improve patient outcomes.
The Connection Between mRNA Degradation Speed and Autoimmune Disease Risk
New research reveals that the speed at which mRNA molecules degrade within cells may play a crucial role in the development of autoimmune diseases, opening new avenues for targeted therapies.
Emerging Challenges of GLP-1 Agonists in PET-CT Imaging
New research at EANM 2025 highlights how GLP-1 receptor agonists can alter PET-CT scans, potentially leading to misdiagnosis in cancer imaging. Awareness and careful medication documentation are key to accurate interpretation.
